Redx Pharma PLC (LON:REDX), the drug discovery and development company focused on cancer and fibrosis has appointed Dr Jane Robertson as its chief medical officer.
She is a well respected UK haemato-oncologist with more than 17 years' experience of clinical development in oncology (cancer treatment) and has a breadth of experience investigating multiple tumours and agents.
Dr Robertson is currently the chief medical officer at Achilles Therapeutics, a biotech company focused on the creation of a personalised T cell therapy directed against clonal tumour neoantigens. She will commence her role at Redx at the beginning of March next year.
She has previously held a number of senior research & development leadership roles at AstraZeneca Oncology, notably leading the development of the first in class PARP inhibitor, olaparib.
She will take over from Dr Andrew Saunders following a handover period. Dr Saunders is quitting Redx to pursue other opportunities.
“As our chief medical officer, her extensive and varied experience in big pharma, biotech and clinical practice will be invaluable as we further progress our pipeline into clinical development,” said Lisa Anson, the chief executive officer of Redx in a statement.
"On behalf of all of Redx and the board, I would like to thank Andrew for his great work in overseeing the transition of RXC004 into phase 1 and his strategic guidance in our planned future development plans for RXC004," Anson added.